title: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.
abstract: We conducted a double-blind, placebo-controlled study of 40 patients (aged 19 to 60 years) with clinical definite relapsing remitting (RR) MS and brain MRI confirmed. Patients were randomly assigned to receive a loading dose of immunoglobulin IgG (0.4 g/kg/body weight per day for 5 consecutive days), followed by single booster doses (0.4 g/kg/body weight) or placebo once every 2 months for 2 years. The primary outcome measures were change in the yearly exacerbation rate (YER), proportion of exacerbation-free patients, and time until first exacerbation. Neurologic disability, exacerbation severity, and changes in brain MRI lesion score were the secondary outcome measures, all determined at baseline, 1 year, and on completion. Treated patients showed a reduction in YER from 1.85 to 0.75 after 1 year and 0.42 after 2 years versus 1.55 to 1.8 after 1 year and to 1.4 after 2 years in the placebo group (p = 0.0006, overall), reflecting a 38.6% reduction in relapse rate. Six patients in the IVIg group were exacerbation free throughout the 2-year period of the study, whereas none were exacerbation free in the placebo group. The median time to first exacerbation was 233 days in the IVIg group versus 82 days in the placebo group (p = 0.003). Neurologic disability as measured by the Expanded Disability Status Scale (EDSS score) decreased by 0.3 in the IVIg group and increased by 0.15 in the placebo group. Total lesion score evaluated by brain MRI did not show a significant difference between groups. Side effects were minor and occurred in only 19 of 630 (3.0%) infusions administered in both groups. Our results suggest that IVIg may be safe and effective in reducing the frequency of exacerbations in RR-MS.
authors.affiliation: Multiple Sclerosis Center, Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Achiron
authors.forename: U
authors.initials: U
authors.lastname: Gabbay
authors.forename: R
authors.initials: R
authors.lastname: Gilad
authors.forename: S
authors.initials: S
authors.lastname: Hassin-Baer
authors.forename: Y
authors.initials: Y
authors.lastname: Barak
authors.forename: M
authors.initials: M
authors.lastname: Gornish
authors.forename: A
authors.initials: A
authors.lastname: Elizur
authors.forename: Y
authors.initials: Y
authors.lastname: Goldhammer
authors.forename: I
authors.initials: I
authors.lastname: Sarova-Pinhas
mesh_terms: D000328:Adult; D001921:Brain / Q000473:pathology; D004185:Disability Evaluation; D018572:Disease-Free Survival; D004311:Double-Blind Method; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D010919:Placebos; D011336:Probability; D012008:Recurrence; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D016756:Immunoglobulins, Intravenous; D010919:Placebos